非活动性肺结核人群的流行病学特征和预防干预

doi:10.3969/j.issn.1000-6621.2020.11.016

摘要/Abstract

摘要：

Houben博士等利用高斯过程回归模型估算我国约有3.5亿人感染结核分枝杆菌(MTB),是世界上MTB感染负担最重的国家之一。2020年,世界卫生组织发布的《结核病综合指南:预防性治疗》中提出“有既往结核病史或者非活动性肺结核病灶者因有更高的发病风险也应该成为暴露后干预的目标人群”。美国和加拿大等国家均将提示有既往肺结核病史的肺部纤维化病灶人群作为潜伏性结核感染检测和治疗的目标人群。目前,我国暂未对有非活动性肺结核人群进行系统干预。考虑到结核病高负担国家和地区可能同样存在较重的非活动性肺结核负担,针对这一高危人群开展活动性结核病的常规监测和早诊早治,并对潜伏性结核感染者开展预防性干预将可能对降低社区发病率做出重要贡献。

关键词: 分枝杆菌,结核, 非活动性结核病, 人群监测, 预防和防护用药

Abstract:

China is one of the countries with the highest burden of Mycobacterium tuberculosis (MTB) infection in worldwide with 350 million people were infected as estimated by Dr. Houben and colleagues using Gaussian process regression model. The guidelines on tuberculosis (TB) preventive treatment updated by the World Health Organization in 2020 recommended that “A history of prior TB or TB preventive treatment should not be a contraindication for preventive treatment in case of exposure, following the exclusion of reactivated disease. These individuals, including those with fibrotic radiological lesions, may be at increased risk of progression.” Individuals with chest radiography abnormalities suggestive of prior healed TB has been recommended as targets for latent tuberculosis infection (LTBI) testing and treatment in American and Canada. In countries and areas with high burden of TB,considering the potential high burden of inactive TB, enhancing active case finding and LTBI preventive treatment in this high-risk group might benefit TB incidence decline in a community level.

Key words: Mycobacterium tuberculosis, Inactive tuberculosis, Population surveillance, Protective agents

杜莹, 张彬, 王大宽, 张浩然, 辛赫男, 金奇, 高磊. 非活动性肺结核人群的流行病学特征和预防干预[J]. 中国防痨杂志, 2020, 42(11): 1232-1236. doi: 10.3969/j.issn.1000-6621.2020.11.016

DU Ying, ZHANG Bin, WANG Da-kuan, ZHANG Hao-ran, XIN He-nan, JIN Qi, GAO Lei. Epidemiology and preventive intervention of inactive tuberculosis[J]. Chinese Journal of Antituberculosis, 2020, 42(11): 1232-1236. doi: 10.3969/j.issn.1000-6621.2020.11.016

参考文献 31

[1]	World Health Organization. Global tuberculosis report 2019. Geneva: World Health Organization, 2019.
[2]	Houben RM, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med, 2016,13(10):e1002152. doi: 10.1371/journal.pmed.1002152. doi: 10.1371/journal.pmed.1002152 URL pmid: 27780211
[3]	Hartman-Adams H, Clark K, Juckett G. Update on latent tuberculosis infection. Am Fam Physician, 2014,89(11):889-896. URL pmid: 25077395
[4]	中华人民共和国国家卫生健康委员会办公厅.中国结核病预防控制工作技术规范中国结核病预防控制工作技术规范(2020年版). 国卫办疾控函〔2020〕279号. 2020-04-02.
[5]	高磊, 金奇. 关口前移:结核潜伏感染及其控制. 中国防痨杂志, 2018,40(8):791-795. doi: 10.3969/j.issn.1000-6621.2018.08.003.
[6]	艾静文, 阮巧玲, 张文宏. 结核分枝杆菌潜伏感染预防性治疗的进展. 中国防痨杂志, 2015,37(1):80-85. doi: 10.3969/j.issn.1000-6621.2015.01.015.
[7]	中华人民共和国国家卫生和计划生育委员会. WS 196—2017结核病分类. 2017-11-09.
[8]	Nachiappan AC, Rahbar K, Shi X, et al. Pulmonary Tuberculosis: Role of Radiology in Diagnosis and Management. Radiographics, 2017,37(1):52-72. doi: 10.1148/rg.2017160032. doi: 10.1148/rg.2017160032 URL pmid: 28076011
[9]	Grzybowski S, Fishaut H, Rowe J, et al. Tuberculosis among patients with various radiologic abnormalities, followed by the chest clinic service. Am Rev Respir Dis, 1971,104(4):605-608. doi: 10.1164/arrd.1971.104.4.605. doi: 10.1164/arrd.1971.104.4.605 URL pmid: 5094062
[10]	Nolan CM, Elarth AM. Tuberculosis in a cohort of Southeast Asian Refugees. A five-year surveillance study. Am Rev Respir Dis, 1988,137(4):805-809. doi: 10.1164/ajrccm/137.4.805. doi: 10.1164/ajrccm/137.4.805 URL pmid: 3354985
[11]	Kim HJ, Baek S, Kim HJ, et al. The impact of smoking on airflow limitation in subjects with history of asthma and inactive tuberculosis. PLoS One, 2015,10(4):e0125020. doi: 10.1371/journal.pone.0125020. doi: 10.1371/journal.pone.0125020 URL pmid: 25915938
[12]	Oh CM, Roh YH, Lim D, et al. Pulmonary Tuberculosis is Associated with Elevated Risk of Lung cancer in Korea: The Nationwide Cohort Study. J Cancer, 2020,11(7):1899-1906. doi: 10.7150/jca.37022. doi: 10.7150/jca.37022 URL pmid: 32194800
[13]	Uzorka JW, Wallinga J, Kroft LJM, et al. Radiological signs of latent tuberculosis on chest radiography: a systematic review and Meta-analysis. Open Forum Infect Dis, 2019, 6(7):ofz313. doi: 10.1093/ofid/ofz313.
[14]	Jeong YJ, Yoon S, Koo HK, et al. Positive tuberculin skin test or interferon-gamma release assay in patients with radiographic lesion suggesting old healed tuberculosis. J Korean Med Sci, 2012,27(7):761-766. doi: 10.3346/jkms.2012.27.7.761. doi: 10.3346/jkms.2012.27.7.761 URL pmid: 22787371
[15]	Lin PL, Ford CB, Coleman MT, et al. Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing. Nat Med, 2014,20(1):75-79. doi: 10.1038/nm.3412. doi: 10.1038/nm.3412 URL pmid: 24336248
[16]	Pai M, Behr MA, Dowdy D, et al. Tuberculosis. Nat Rev Dis Primers, 2016,2:16076. doi: 10.1038/nrdp.2016.76. doi: 10.1038/nrdp.2016.76 URL pmid: 27784885
[17]	Cadena AM, Fortune SM, Flynn JL. Heterogeneity in tuberculosis. Nat Rev Immunol, 2017,17(11):691-702. doi: 10.1038/nri.2017.69. doi: 10.1038/nri.2017.69 URL pmid: 28736436
[18]	Ramakrishnan L. Revisiting the role of the granuloma in tuberculosis. Nat Rev Immunol, 2012,12(5):352-366. doi: 10.1038/nri3211. doi: 10.1038/nri3211 URL pmid: 22517424
[19]	Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med, 2000,161(4 Pt 2):S221-S247. doi: 10.1164/ajrccm.161.supplement_3. ats600. doi: 10.1164/ajrccm.161.supplement_3.ats600 URL pmid: 10764341
[20]	Walter ND, Painter J, Parker M, et al. Persistent latent tuberculosis reactivation risk in United States immigrants. Am J Respir Crit Care Med, 2014,189(1):88-95. doi: 10.1164/rccm.201308-1480OC. doi: 10.1164/rccm.201308-1480OC URL pmid: 24308495
[21]	Shimouchi A, Ozasa K. The incidence rate of active pulmonary tuberculosis among adult population with fibrotic lesions. Kekkaku, 2003,78(1):5-13. URL pmid: 12655700
[22]	Zhang CY, Zhao F, Xia YY, et al. Prevalence and risk factors of active pulmonary tuberculosis among elderly people in China: a population based cross-sectional study. Infect Dis Poverty, 2019,8(1):7. doi: 10.1186/s40249-019-0515-y. doi: 10.1186/s40249-019-0515-y URL pmid: 30654836
[23]	Xin H, Zhang H, Yang S, et al. 5-Year follow-up of active tuberculosis development from latent infection in rural China. Clin Infect Dis, 2020,70(5):947-950. doi: 10.1093/cid/ciz581. doi: 10.1093/cid/ciz581 URL pmid: 31253988
[24]	Gao L, Zhang H, Xin H, et al. Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study. Eur Respir J, 2018,52(6):1801470. doi: 10.1183/13993003.01470-2018. doi: 10.1183/13993003.01470-2018 URL pmid: 30361241
[25]	Uzorka JW, Kroft LJM, Bakker JA, et al. Abnormalities suggestive of latent tuberculosis infection on chest radiography; how specific are they?. J Clin Tuberc Other Mycobact Dis, 2019,15:100089. doi: 10.1016/j.jctube.2019.01.004. doi: 10.1016/j.jctube.2019.01.004 URL pmid: 31720416
[26]	den Boon S, van Lill SW, Borgdorff MW, et al. High prevalence of tuberculosis in previously treated patients, Cape Town, South Africa. Emerg Infect Dis, 2007,13(8):1189-1194. doi: 10.3201/eid1308.051327. doi: 10.3201/eid1308.051327 URL pmid: 17953090
[27]	Solsona Peiró J, de Souza Galvão ML, Altet Gómez MN. Inactive fibrotic lesions versus pulmonary tuberculosis with negative bacteriology. Arch Bronconeumol, 2014,50(11):484-489. doi: 10.1016/j.arbres.2013.07.009. doi: 10.1016/j.arbres.2013.07.009 URL pmid: 24713269
[28]	Gao L, Bai L, Liu J, et al. Annual risk of tuberculosis infection in rural China: a population-based prospective study. Eur Respir J, 2016,48(1):168-178. doi: 10.1183/13993003.00235-2016. doi: 10.1183/13993003.00235-2016 URL pmid: 27230438
[29]	International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ, 1982,60(4):555-564. URL pmid: 6754120
[30]	World Health Organization. WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment. Geneva: World Health Organization, 2020.
[31]	Tait DR, Hatherill M, Van Der Meeren O, et al. Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis. N Engl J Med, 2019,381(25):2429-2439. doi: 10.1056/NEJMoa1909953.